Mohammed Shanshal

Topical steroid withdrawal: old problem, new terminology, and diagnostic inflation in the social-media era

Mohammed Shanshal

Topical steroid withdrawal is increasingly discussed in clinical practice and online, but the label is often applied to several different post-steroid presentations. This letter argues for a balanced approach that recognises possible withdrawal reactions while applying a diagnosis of TSW only when …

gb (code pays fourni par la source)

Male genital lichen sclerosus after circumcision in infancy: pseudo-preputial occlusion in a patient with increased body mass index

Zahraa Al-Hamamy, Hiba Maqdasi, Ali Al‐Mamoori, Mohammed Shanshal et autres

Male genital lichen sclerosus is less common after circumcision in infancy, but it may occur when redundant penile shaft or base skin recreates a pseudo-preputial occlusive environment. We report a biopsy-confirmed case of genital lichen sclerosus in a 27-year-old man who was …

iq, gb (code pays fourni par la source)

Delayed cutaneous depigmentation in Vogt–Koyanagi–Harada disease

Mohammed Shanshal, Sumbel Khan

Vogt–Koyanagi–Harada disease may present to dermatologists through delayed integumentary findings after the acute ocular phase. This image-based case shows right frontotemporal depigmentation developing after bilateral panuveitis, with funduscopic changes compatible with convalescent disease.

gb (code pays fourni par la source)

Bilateral Gram‐Negative Facial Abscesses After Polynucleotide Injections

Mohammed Shanshal, Radhika Bali, Emily Moon, Rosanna Fox et autres

ABSTRACT Background Polynucleotide (PN) injections are increasingly used for facial rejuvenation, but severe infectious complications remain poorly characterized. Case Report We report an otherwise healthy 57‐year‐old woman who developed progressive bilateral cheek inflammation after facial PN injections. Initial features resembled expected post‐injection …

gb (code pays fourni par la source)

Cellulitis Caused by Mixed Infection with Group A Streptococci and Non-Toxigenic tox-Gene-Bearing Corynebacterium diphtheriae: A Case Report

Mohammed Shanshal, Pallavi Sanjay Wadhe

Introduction: Cutaneous diphtheria has re-emerged in Europe, often presenting as skin-limited disease. Uncertainty around diagnosis, infection control, and toxigenicity testing can delay appropriate management. Case Presentation: A 62-year-old woman experiencing homelessness presented with a 2-week history of a painful lower-leg eruption. This …

gb (code pays fourni par la source)

Topical Statins in Porokeratosis: Case Report with Focused Literature Review

Mohammed Shanshal

Introduction: Porokeratosis is a disorder of keratinisation linked to mevalonate pathway defects and often resistant to conventional therapy. Topical statins, which target this pathway directly, represent a rational mechanism-based treatment. Case Presentation: A 63-year-old woman with disseminated superficial actinic porokeratosis (DSAP), refractory …

gb (code pays fourni par la source)

HPV‐6 Positive Eruptive Verruca Vulgaris After Upadacitinib Initiation for Severe Atopic Dermatitis

Mohammed Shanshal, Emily Moon, Georgios Kallikas

ABSTRACT Oral JAK‐1 inhibitors for atopic dermatitis (AD) are associated with an increased risk of cutaneous viral infections, particularly herpes zoster. Emerging case reports further suggest a link to eruptive human papillomavirus (HPV) disease. A 23‐year‐old transgender man (female‐to‐male) with severe AD …

gb (code pays fourni par la source)

Abstract 3931: Immune cell profile changes in patients treated with tarlatamab for extensive stage small cell lung cancer in real world practice.

Dhauna Karam Prasad, Andre De Menezes Silva Corraes, Malvika Gupta, Audrey Ma et autres

Abstract Background: Tarlatamab, a Delta-like ligand (DLL3)/CD3-targeted bispecific T-cell engager (TCE) is FDA approved in patients (pts) with extensive stage small cell lung cancer (ES-SCLC), after progression on frontline chemoimmunotherapy. We aimed to evaluate the immune cell profile in pts who received …

us (code pays fourni par la source)

Dual‐Biologic Therapy in Refractory Bullous Pemphigoid: A Focused Review of Rituximab–Omalizumab and Omalizumab–Dupilumab

Mohammed Shanshal

Background Bullous pemphigoid (BP) is the commonest autoimmune subepidermal blistering disease. Refractory cases and patients with comorbidities limiting conventional immunosuppression remain difficult to treat. Dual‐biologic therapy has emerged as a rescue strategy. Methods We reviewed PubMed and Embase from inception to 1 …

gb (code pays fourni par la source)

Granulomatous Dermatoses and Sarcoidosis/Sarcoid‐Like Disease During Dupilumab Therapy: A Phenotype‐Based Case‐Level Review

Mohammed Shanshal, George Karanasios

Background Dupilumab, an interleukin‐4 receptor alpha antagonist, is widely used across Type 2 inflammatory diseases. Case reports have described granulomatous inflammation arising or worsening during treatment, but the reported phenotypes are scattered across dermatology, respiratory and allergy literature. Objective To characterise the …

gb (code pays fourni par la source)

Oral JAK Inhibitors as Rescue Therapy for Cosmetic Injectable–Associated Granulomatous Reactions: A Narrative Synthesis of Case Reports

Mohammed Shanshal, George Karanasios

Background Cosmetic injectable procedures, including dermal fillers and mesotherapy, can trigger delayed granulomatous reactions that are diagnostically challenging and may be refractory to conventional therapies. Oral Janus kinase (JAK) inhibitors have recently emerged in scattered reports as off‐label rescue options. Objective To …

gb (code pays fourni par la source)

Lorlatinib and neurocognitive adverse events: characterization, risk factors, and the potentially mitigative role of social support

Ryan M. Brown, Katie E. Smith, Mohammed Shanshal, Anastasios Dimou et autres

us (code pays fourni par la source)